

Notes to the Disclosure Report 2023

In view of the current situation, we would like to point out that the global functions of the Viatriis Group commission and pay for, inter alia, expert opinions, research and development contracts, and consulting activities of key opinion leaders / world-renowned experts (HCP / HCO) through the Swiss subsidiary "BGP Products Operations GmbH".

This may result in a reporting obligation for paid activities of Swiss HCP / HCO on behalf of the global functions of the Viatriis Group outside the Swiss market as part of the Transfer of Value disclosure in accordance with the Scienceindustries guidelines.

The monetary benefits listed in the report of "BGP Products Operations GmbH" were granted for activities commissioned by global functions. These projects are unrelated to the Swiss national companies of the Viatriis Group "Mylan Pharma GmbH" and "Viatriis Pharma GmbH" and were commissioned and carried out without their knowledge.

It should also be noted that the total amount of benefits granted per HCP also includes travel expenses incurred by the company for activities abroad. These can make up a significant proportion in individual cases but expressly do not constitute a fee. Please refer to the itemized breakdown.

If you have any questions or require further information, please do not hesitate to contact us via e-mail at.

infoch@viatriis.com

Kind regards

VIATRIS (Schweiz)